Kepos Capital’s Pacira BioSciences PCRX Stock Holding History

Kepos Capital’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-4,537	Closed	-$173K	–	406
2019 Q3	$173K	Sell	4,537 -10,367	-70%	-$414K	0.02%	279
2019 Q2	$648K	Hold	14,904	–	–	0.07%	192
2019 Q1	$567K	Buy	+14,904	New	+$582K	0.04%	264

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Kepos Capital's PCRX Position: Q4 2019 in Review

Kepos Capital sold out of Pacira BioSciences (PCRX) in Q4 2019, closing a stake of 4,537 shares — an estimated $173K sold.

Kepos Capital first reported a position in PCRX in Q1 2019 and held it in 3 quarters. The position peaked at $648K in Q2 2019. 231 funds tracked by Wall St. Rank hold PCRX as of Q4 2019.

Kepos Capital reported no remaining Pacira BioSciences position as of Q4 2019 after selling out during the quarter.
Kepos Capital sold 4,537 Pacira BioSciences shares in Q4 2019, an estimated $173K.
Kepos Capital first reported a position in Pacira BioSciences in Q1 2019 and held it in 3 quarters.
Kepos Capital's Pacira BioSciences position peaked at $648K in Q2 2019.
231 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2019.

Based on Kepos Capital's 13F filing for Q4 2019, filed 13 Feb 2020.